News

Cellares, the first Integrated Development and Manufacturing Organization (IDMO) dedicated to clinical and industrial-scale cell therapy manufacturing, announced that global…
Read More...

Bayer has opened a new cell therapy manufacturing facility in Berkeley, California, USA, to offer cell therapies to patients worldwide. The $250 million investment will be used to…
Read More...

Swedish biotech company Salipro Biotech AB and Estonian biotechnology company Icosagen announced that they entered into a multi-target antibody research agreement to advance drug…
Read More...

BioMap announced a groundbreaking strategic collaboration with Sanofi to co-develop cutting-edge AI modules for biotherapeutic drug discovery leveraging BioMap’s AI platform. “As the…
Read More...

Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces an exclusive license agreement with CanariaBio, a Korean biopharmaceutical company focused on the…
Read More...

Ultimovacs ASA, a clinical-stage biotechnology leader in novel immunotherapeutic cancer vaccines, announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug…
Read More...

Novartis, a global leader in immuno-dermatology and rheumatology, announced that the US Food and Drug Administration (FDA) has approved an intravenous (IV) formulation of Cosentyx…
Read More...

Agomab Therapeutics NV announced that it received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for AGMB-129 for the potential treatment of Fibrostenosing…
Read More...

AbbVie announced that it has exercised its exclusive right and completed the acquisition of Mitokinin, a discovery-stage biotechnology company developing a potentially first-in-class…
Read More...

Bayer AG has entered into an antibody discovery, option, and license agreement with Twist Bioscience Corporation, a company offering high-quality synthetic DNA using its silicon…
Read More...

Positive results from the T2NOW Phase III trial demonstrated significant reduction in A1C, a marker of average blood sugar, for patients treated with Forxiga (dapagliflozin) compared…
Read More...

Sanofi and Teva Pharmaceuticals, a U.S. subsidiary of Teva Pharmaceutical Industries Ltd. announce a collaboration to co-develop and co-commercialize asset TEV’574, currently in Phase…
Read More...

ADVANZ PHARMA Corp. Limited, a UK headquartered global pharmaceutical company with a strategic focus on speciality, hospital and rare disease medicines in Europe, Canada, and Australia,…
Read More...

Regeneron Pharmaceuticals, Inc. and Intellia Therapeutics, Inc. announced an expanded research collaboration to develop additional in vivo CRISPR-based gene editing therapies focused on…
Read More...

Eli Lilly and Company and POINT Biopharma Global, Inc. announced a definitive agreement for Lilly to acquire POINT, a radiopharmaceutical company with a pipeline of clinical and…
Read More...

Karuna Therapeutics, Inc., a biopharmaceutical company driven to discover, develop, and deliver transformative medicines for people living with psychiatric and neurological conditions,…
Read More...

Maryland-based biotech company Deka Biosciences announced that it has successfully closed a USD $20 Million Series B2 financing with a syndicate of life science investors led by MPM…
Read More...

Shanghai Stock Exchange listed company HitGen Inc. announced that it has entered into a partnership with The Structural Genomics Consortium ("SGC"), a public-private partnership that…
Read More...

Amicus Therapeutics announced that the U.S. Food and Drug Administration (FDA) has approved Pombiliti™ (cipaglucosidase alfa-atga) + Opfolda™ (miglustat) 65mg capsules. This…
Read More...

Regeneron Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) for odronextamab to…
Read More...